JPH07506005A - 改変型毛様体神経栄養因子 - Google Patents
改変型毛様体神経栄養因子Info
- Publication number
- JPH07506005A JPH07506005A JP6510157A JP51015794A JPH07506005A JP H07506005 A JPH07506005 A JP H07506005A JP 6510157 A JP6510157 A JP 6510157A JP 51015794 A JP51015794 A JP 51015794A JP H07506005 A JPH07506005 A JP H07506005A
- Authority
- JP
- Japan
- Prior art keywords
- cntf
- modified
- human
- lau
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Description
Claims (30)
- 1.改変Gln63→Argを有するヒト毛様体神経栄養因子(CNTF)。
- 2.RPN186、RPN189、RPN218、RPN219、RPN228 から選択される請求項1に記載の改変型ヒト毛様体神経栄養因子(CNTF)。
- 3.請求項1に記載の改変型ヒトCNTFをコードする、単離且つ精製されたD NA分子。
- 4.請求項2に記載の改変型ヒトCNTFをコードする、単離且つ精製されたD NA分子。
- 5.組換えDNA分子中の発現調節配列に作動的に結合された請求項3に記載の DNA分子を含む組換えDNA分子。
- 6.組換えDNA分子中の発現調節配列に作動的に結合された請求項4に記載の DNA分子を含む組換えDNA分子。
- 7.請求項5又は6に記載の組換えDNA分子で形質転換された単細胞宿主。
- 8.細菌、酵母及び他の菌類、動物細胞並びに植物細胞から選択される請求項7 に記載の単細胞宿主。
- 9.DNA分子が宿主により発現されるように請求項5又は6に記載のDNA分 子を含む組換え宿主を増殖させ、発現された毛様体神経栄養因子タンパク質を単 離することを含む改変型CNTF分子を製造する方法。
- 10.前記宿主が真核細胞である請求項9に記載の方法。
- 11.前記宿主が原核細胞である請求項9に記載の方法。
- 12.医薬上適する担体と共に請求項1又は2に記載の改変型ヒトCNTFを含 む医薬組成物。
- 13.神経系の疾患又は障害を治療すべくヒト又は動物の身体を治療する方法に 使用するための請求項1又は2に記載の改変型ヒトCNTF。
- 14.前記疾患又は障害が変性疾患である請求項13に記載の改変型CNTF。
- 15.前記疾患又は障害が脊髄に関わる請求項13に記載の改変型CNTF。
- 16.前記疾患又は障害が運動ニューロンに関わる請求項13に記載の改変型C NTF。
- 17.前記疾患又は障害が、ベル麻痺のような顔面神経の運動ニューロンに関わ る請求項16に記載の改変型CNTF。
- 18.前記変性疾患が筋委縮性側索硬化症である請求項14に記載の改変型CN TF。
- 19.前記変性疾患が、末梢神経障害、アルツハイマー病、パーキンソン病又は ハンテントン舞踏病からなる群から選択される請求項14に記載の改変型CNT F。
- 20.神経系の疾患又は障害が神経系に対する損傷を含む請求項13に記載の改 変型CNTF。
- 21.前記損傷が、外傷、手術、梗塞、感染又は悪性腫瘍によって引き起こされ る請求項20に記載の改変型CNTF。
- 22.前記損傷が毒物にさらされることによって引き起こされる請求項20に記 載の改変型CNTF。
- 23.神経系の疾患又は障害がコリン作用性ニューロンに関わる請求項13に記 載の改変型CNTF。
- 24.前記疾患又は障害が筋委縮症に関わる請求項13に記載の改変型CNTF 。
- 25.萎縮症が、除神経、慢性疲労、代謝性ストレス及び栄養失調から引き起こ される請求項24に記載の改変型CNTF。
- 26.萎縮症が、筋ジストロフィー症候群、先天性筋障害、筋肉の炎症性疾患又 は中毒性障害から引き起こされる請求項24に記載の改変型CNTF。
- 27.萎縮症が、神経外傷、末梢神経障害、薬物若しくは毒物誘導損傷又は運動 神経細胞障害から引き起こされる請求項24に記載の改変型CNTF。
- 28.前記疾患又は障害が海馬細胞に関わる請求項13に記載の改変型CNTF 。
- 29.生物学的活性及び/又は結合親和性が増進したヒトタンパク質のスクリー ニング法であって、野生型ヒトタンパク質のSDS−PAGE電気泳動移動度を 決定し; 前記野生型ヒトタンパク質にアミノ酸置換を導入し;置換されたタンパク質の電 気泳動移動度を野生型タンパク質の電気泳動移動度と比較し; 電気泳動移動度が変更された置換タンパク質を、野生型タンパク質の電気泳動移 動度と比較して同定し;同定されたタンパク質の生物学的活性及び/又は結合親 和性を測定することを含む前記方法。
- 30.野生型ヒトタンパク質中で置換されたアミノ酸配列が、異なる動物種の相 同タンパク質のアミノ酸配列に相当する請求項29に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US959,284 | 1992-10-09 | ||
US07/959,284 US5349056A (en) | 1992-10-09 | 1992-10-09 | Modified ciliary neurotrophic factors |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07506005A true JPH07506005A (ja) | 1995-07-06 |
JP2702811B2 JP2702811B2 (ja) | 1998-01-26 |
Family
ID=25501875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6510157A Expired - Fee Related JP2702811B2 (ja) | 1992-10-09 | 1993-10-08 | 改変型毛様体神経栄養因子 |
Country Status (14)
Country | Link |
---|---|
US (5) | US5349056A (ja) |
EP (1) | EP0666912B1 (ja) |
JP (1) | JP2702811B2 (ja) |
AT (1) | ATE151460T1 (ja) |
AU (1) | AU667996B2 (ja) |
CA (1) | CA2132954C (ja) |
DE (1) | DE69309702T2 (ja) |
DK (1) | DK0666912T3 (ja) |
ES (1) | ES2099981T3 (ja) |
GR (1) | GR3024039T3 (ja) |
HK (1) | HK1007767A1 (ja) |
IL (1) | IL107213A0 (ja) |
WO (1) | WO1994009134A2 (ja) |
ZA (1) | ZA937482B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998010785A1 (fr) * | 1996-09-13 | 1998-03-19 | Advanced Medicine Research Institute | Compositions ophtalmiques de facteurs neurotrophiques, remedes pour troubles fonctionnels du nerf optique et procede de traitement de tels troubles |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5141856A (en) * | 1989-01-05 | 1992-08-25 | Synergen, Inc. | Expression of purified ciliary neurotrophic factor |
US6472178B1 (en) * | 1998-02-27 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof |
US5349056A (en) * | 1992-10-09 | 1994-09-20 | Regeneron Pharmaceuticals | Modified ciliary neurotrophic factors |
TW248552B (ja) * | 1993-06-01 | 1995-06-01 | Onoda Yakuhin Kogyo Kk | |
WO1995018150A1 (fr) * | 1993-12-29 | 1995-07-06 | Sumitomo Pharmaceuticals Company, Limited | Nouveau facteur neurotrophique ciliaire humain |
AU7204996A (en) * | 1995-10-02 | 1997-04-28 | Cytotherapeutics, Inc. | Method for treating amyotrophic lateral sclerosis |
US5859311A (en) * | 1995-11-27 | 1999-01-12 | University Of Kentucky Research Foundation | Transgenic mice which overexpress neurotrophin-3 (NT-3) and methods of use |
IT1284867B1 (it) | 1996-07-10 | 1998-05-22 | Angeletti P Ist Richerche Bio | Varianti del fattore neurotrofico ciliare umano (hcntf) con uno spettro di azione differente dalla molecola di tipo selvatico |
IT1288388B1 (it) * | 1996-11-19 | 1998-09-22 | Angeletti P Ist Richerche Bio | Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia |
US20040120891A1 (en) * | 1998-12-21 | 2004-06-24 | Craig Hill | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
HUP0203057A3 (en) * | 1999-08-13 | 2005-07-28 | Regeneron Pharma | Modified ciliary neurotrophic factor, method of making and methods of use thereof |
US7442370B2 (en) * | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
AU2002253942A1 (en) * | 2001-02-12 | 2002-08-28 | Michael Amling | Methods and compositions for control of bone formation via modulation of ciliary neurotrophic factor activity |
US7276580B2 (en) * | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
WO2003049673A2 (en) | 2001-12-05 | 2003-06-19 | Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of sympathetic tone |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
WO2004037281A1 (en) * | 2002-10-24 | 2004-05-06 | The University Of British Columbia | Methods for neuroprotection |
JP4571776B2 (ja) * | 2002-11-05 | 2010-10-27 | Jx日鉱日石エネルギー株式会社 | 潤滑油組成物 |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2004094592A2 (en) | 2003-04-18 | 2004-11-04 | Biogen Idec Ma Inc. | Polymer-conjugated glycosylated neublastin |
GEP20084406B (en) | 2003-05-30 | 2008-06-25 | Ranbaxy Lab Ltd | Substituted pyrrole derivatives and their use as hmg-co inhibitors |
US20050064555A1 (en) * | 2003-07-09 | 2005-03-24 | Xencor, Inc. | Ciliary neurotrophic factor variants |
WO2005028438A1 (ja) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
KR20110126732A (ko) * | 2004-08-19 | 2011-11-23 | 바이오겐 아이덱 엠에이 인코포레이티드 | 뉴블라스틴 변형체 |
NZ553420A (en) | 2004-08-19 | 2010-02-26 | Biogen Idec Inc | Refolding transforming growth factor beta family proteins |
EP1814590B2 (en) | 2004-11-01 | 2013-12-11 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
US20060178301A1 (en) * | 2005-02-04 | 2006-08-10 | Mathias Jurs | Albumin-fused ciliary neurotrophic factor |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
ES2574014T3 (es) | 2005-05-30 | 2016-06-14 | Msd K.K. | Derivado de piperidina novedoso |
EP1916239A4 (en) | 2005-08-10 | 2009-10-21 | Banyu Pharma Co Ltd | PYRIDONE COMPOUND |
EP1921065B1 (en) | 2005-08-24 | 2010-10-20 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
WO2007029847A1 (ja) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | 二環性芳香族置換ピリドン誘導体 |
EP1940842B1 (en) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
BRPI0617621A2 (pt) | 2005-10-21 | 2011-08-02 | Novartis Ag | combinação de compostos orgánicos |
AU2006307046A1 (en) | 2005-10-27 | 2007-05-03 | Msd K.K. | Novel benzoxathiin derivative |
AU2006313430B2 (en) | 2005-11-08 | 2012-09-06 | Ranbaxy Laboratories Limited | Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
MY146564A (en) | 2005-11-10 | 2012-08-30 | Msd Kk | Aza-substituted spiro derivatives |
BRPI0707482A2 (pt) * | 2006-02-02 | 2011-05-03 | Rinat Neuroscience Corp | métodos para tratar perda indesejada de peso ou distúbios de alimentação por administração de um agonista de trkb, bem como uso de nt-4/5 e de um agonista de trkb |
WO2007088479A1 (en) * | 2006-02-02 | 2007-08-09 | Rinat Neuroscience Corp. | Methods for treating obesity by administering a trkb antagonist |
TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
EP1993590B1 (en) * | 2006-03-01 | 2013-12-25 | Biogen Idec MA Inc. | Compostions and methods for administering gdnf ligand family proteins |
EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
WO2008038692A1 (fr) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | dÉrivÉ de diarylcÉtimine |
RU2009123491A (ru) * | 2006-12-20 | 2010-12-27 | Ринат Ньюросайенс Корпорейшн (Us) | АГОНИСТЫ TrkB ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ НАРУШЕНИЙ |
AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
ES2476253T3 (es) | 2007-05-01 | 2014-07-14 | Biogen Idec Ma Inc. | P�ptidos de neublastina para su uso en el aumento de la vascularizaci�n en tejido con flujo sanguíneo deteriorado |
US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US20110135648A1 (en) * | 2007-08-08 | 2011-06-09 | Biogen Idec Ma Inc. | Anti-neublastin antibodies and uses thereof |
US20100297081A1 (en) * | 2007-12-18 | 2010-11-25 | Huang Yanshan | Pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein |
CA2714617A1 (en) | 2008-03-06 | 2009-09-11 | Banyu Pharmaceutical Co., Ltd. | Alkylaminopyridine derivative |
US20110015198A1 (en) | 2008-03-28 | 2011-01-20 | Banyu Pharmaceutical Co., Inc. | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism |
EP3239170B1 (en) | 2008-06-04 | 2019-03-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP2301936A1 (en) | 2008-06-19 | 2011-03-30 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
EP2319841A1 (en) | 2008-07-30 | 2011-05-11 | Msd K.K. | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
EP2677869B1 (en) | 2011-02-25 | 2017-11-08 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
AU2014219020A1 (en) | 2013-02-22 | 2015-07-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法 |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
JP6769963B2 (ja) | 2014-08-29 | 2020-10-14 | ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ | α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤 |
AU2017342083A1 (en) | 2016-10-14 | 2019-04-11 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | ANTIDIABETIC SPIROCHROMAN COMPOUNDS |
CA3105879A1 (en) | 2018-07-18 | 2020-01-23 | Manzanita Pharmaceuticals, Inc. | Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof |
KR20210111248A (ko) | 2018-11-20 | 2021-09-10 | 테스 파마 에스.알.엘. | α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US4997929A (en) * | 1989-01-05 | 1991-03-05 | Synergen, Inc. | Purified ciliary neurotrophic factor |
HUT62033A (en) * | 1990-03-14 | 1993-03-29 | Fidia Spa | Process for producing human ciliary body neuronotropic factor |
HUT67352A (en) * | 1991-07-23 | 1995-03-28 | Syntex Inc | Recombinant ciliary neurotrophic factor and c-ferminal truncated ciliary neurotrophic factor, their production, and pharmaceutical products for treatment of peripheral nerveinjury, containing them |
US5593857A (en) * | 1991-08-23 | 1997-01-14 | Scios Inc. | Production of homogeneous truncated CNTF |
US5349056A (en) * | 1992-10-09 | 1994-09-20 | Regeneron Pharmaceuticals | Modified ciliary neurotrophic factors |
-
1992
- 1992-10-09 US US07/959,284 patent/US5349056A/en not_active Expired - Lifetime
-
1993
- 1993-10-08 CA CA002132954A patent/CA2132954C/en not_active Expired - Fee Related
- 1993-10-08 EP EP93923333A patent/EP0666912B1/en not_active Expired - Lifetime
- 1993-10-08 DE DE69309702T patent/DE69309702T2/de not_active Expired - Lifetime
- 1993-10-08 DK DK93923333.4T patent/DK0666912T3/da active
- 1993-10-08 IL IL107213A patent/IL107213A0/xx unknown
- 1993-10-08 WO PCT/US1993/009649 patent/WO1994009134A2/en active IP Right Grant
- 1993-10-08 ZA ZA937482A patent/ZA937482B/xx unknown
- 1993-10-08 AT AT93923333T patent/ATE151460T1/de active
- 1993-10-08 JP JP6510157A patent/JP2702811B2/ja not_active Expired - Fee Related
- 1993-10-08 AU AU53260/94A patent/AU667996B2/en not_active Ceased
- 1993-10-08 ES ES93923333T patent/ES2099981T3/es not_active Expired - Lifetime
-
1994
- 1994-09-19 US US08/308,736 patent/US5846935A/en not_active Expired - Lifetime
-
1997
- 1997-07-09 GR GR970401694T patent/GR3024039T3/el unknown
-
1998
- 1998-06-26 HK HK98106965A patent/HK1007767A1/xx not_active IP Right Cessation
- 1998-11-20 US US09/197,349 patent/US6440702B1/en not_active Expired - Fee Related
-
2002
- 2002-08-23 US US10/226,759 patent/US20030092129A1/en not_active Abandoned
-
2003
- 2003-03-07 US US10/383,916 patent/US20030220484A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998010785A1 (fr) * | 1996-09-13 | 1998-03-19 | Advanced Medicine Research Institute | Compositions ophtalmiques de facteurs neurotrophiques, remedes pour troubles fonctionnels du nerf optique et procede de traitement de tels troubles |
Also Published As
Publication number | Publication date |
---|---|
JP2702811B2 (ja) | 1998-01-26 |
ATE151460T1 (de) | 1997-04-15 |
WO1994009134A2 (en) | 1994-04-28 |
US20030092129A1 (en) | 2003-05-15 |
ES2099981T3 (es) | 1997-06-01 |
HK1007767A1 (en) | 1999-04-23 |
EP0666912B1 (en) | 1997-04-09 |
DE69309702T2 (de) | 1997-10-30 |
AU667996B2 (en) | 1996-04-18 |
CA2132954A1 (en) | 1994-04-28 |
US6440702B1 (en) | 2002-08-27 |
IL107213A0 (en) | 1994-01-25 |
ZA937482B (en) | 1994-04-26 |
GR3024039T3 (en) | 1997-10-31 |
AU5326094A (en) | 1994-05-09 |
US5846935A (en) | 1998-12-08 |
WO1994009134A3 (en) | 1994-05-26 |
DE69309702D1 (de) | 1997-05-15 |
CA2132954C (en) | 2000-01-18 |
US20030220484A1 (en) | 2003-11-27 |
DK0666912T3 (da) | 1997-09-29 |
EP0666912A1 (en) | 1995-08-16 |
US5349056A (en) | 1994-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07506005A (ja) | 改変型毛様体神経栄養因子 | |
Urfer et al. | The binding epitopes of neurotrophin‐3 to its receptors trkC and gp75 and the design of a multifunctional human neurotrophin. | |
Thoenen et al. | Neurotrophic factors | |
Rosenthal et al. | Primary structure and biological activity of a novel human neurotrophic factor | |
US7528233B2 (en) | Pantropic neurothrophic factors | |
Azmitia et al. | S-100B but not NGF, EGF, insulin or calmodulin is a CNS serotonergic growth factor | |
Petrova et al. | MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons | |
US6767894B1 (en) | Use of ciliary neurotrophic factor | |
März et al. | Sympathetic neurons can produce and respond to interleukin 6 | |
KR100205078B1 (ko) | 염기성 섬유 아세포 성장인자 및 이의 생산방법 | |
Kopelowitz et al. | Influence of codon context on UGA suppression and readthrough | |
JPH07502404A (ja) | 幹細胞阻害タンパク質 | |
Madison et al. | Differential expression of rab3 isoforms in oligodendrocytes and astrocytes | |
Zhang et al. | Expression and purification of recombinant human neuritin from Pichia pastoris and a partial analysis of its neurobiological activity in vitro | |
Kachalsky et al. | Two subsites in the binding domain of the acetylcholine receptor: an aromatic subsite and a proline subsite. | |
PT98694A (pt) | Gene codificador da proteina mk humana | |
Kullander et al. | Two restricted sites on the surface of the nerve growth factor molecule independently determine specific TrkA receptor binding and activation | |
Heller et al. | Analysis of function and expression of the chick GPA receptor (GPAR α) suggests multiple roles in neuronal development | |
Negro et al. | Synthesis, purification, and characterization of human ciliary neuronotrophic factor from E. coli | |
US7144983B1 (en) | Pantropic neurotrophic factors | |
KR940021579A (ko) | 골(骨)-관련 전사 조절인자형 단백질 및 이의 제조방법 | |
Hu et al. | Human fibroblast growth factor-18 stimulates fibroblast cell proliferation and is mapped to chromosome 14p11 | |
US20140171620A1 (en) | Ciliary neurotrophic factor variants | |
KR20210070325A (ko) | 변형된 사람 에리트로포이에틴 | |
KR101545103B1 (ko) | 프로테인 포스파타아제 저해제 2의 신규 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081003 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091003 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091003 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101003 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101003 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111003 Year of fee payment: 14 |
|
LAPS | Cancellation because of no payment of annual fees |